title: Concomitant EGFR inhibitors combined with radiation for treatment of non-small cell lung carcinoma.
abstract: Epidermal growth factor receptor (EGFR) is considered to be one of the key driver genes in non-small cell lung cancer (NSCLC). Several clinical trials have shown great promise of EGFR tyrosine kinase inhibitors (TKIs) in the first-line treatment of NSCLC. Many advances have been made in the understanding of EGFR signal transduction network and the interaction between EGFR and tumor microenvironment in mediating cancer survival and development. The concomitant targeted therapy and radiation is a new strategy in the treatment of NSCLC. A number of preclinical studies have demonstrated synergistic anti-tumor activity in the combination of EGFR inhibitors and radiotherapy in vitro and in vivo. In the present review, we discuss the rationale of the combination of EGFR inhibitors and radiotherapy in the treatment of NSCLC.
authors.affiliation: Department of Clinical Oncology, Weifang People's Hospital, Weifang, China E-mail : jundonggu@aliyun.com.
authors.forename: De-Jie
authors.initials: DJ
authors.lastname: Zheng
authors.forename: Guo-Hua
authors.initials: GH
authors.lastname: Yu
authors.forename: Jian-Feng
authors.initials: JF
authors.lastname: Gao
authors.forename: Jun-Dong
authors.initials: JD
authors.lastname: Gu
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors